Clinical Waivers for Topical Dermatological Products: Formulation and Regulatory Strategies
- Posted by Yogesh Chaudhari
- Posted in News and Events
Dr. L. H. Hiranandani Lecture Series – 5th Lecture: 26 September 2026
The Department of Quality Assurance, Dr. L. H. Hiranandani College of Pharmacy, successfully organized the 5th Lecture of the Dr. L. H. Hiranandani Lecture Series on: “Clinical Waivers for Topical Dermatological Products: Formulation and Regulatory Strategies”
We were privileged to have Dr. Roopali Bhanushali (Otavkar), Ph.D, Senior Principal Scientist, Glenmark Pharmaceuticals Ltd., as the resource person. The session offered valuable insights into global regulatory pathways, Q1/Q2/Q3 sameness, formulation development, advanced product characterization, IVRT/IVPT, and emerging approaches for clinical waivers in topical dermatological products. The engaging discussion highlighted the strong connection between formulation science, product characterization, in-vitro performance and regulatory strategy, making the session highly enriching for our students and faculty.
Sincere thanks to Dr. Roopali Bhanushali (Otavkar), Ph.D for sharing her expertise and valuable industry perspective.
We express our heartfelt gratitude to Dr. Paraag Gide Gide, Principal, for his constant encouragement and support in promoting academic and industry-oriented learning initiatives. Special appreciation to Dr. Meghana Babar for coordinating the lecture and Dr. Vijaya Bhogale for their valuable support in making the event a success. Another enriching academic initiative by the Department of Quality Assurance, fostering meaningful connections between academia, industry and contemporary pharmaceutical practice.
